

PATENT
Attorney Docket No. 208859

EOH CENTER 1600 2300

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

ROELVINK et al.

Application No. 09/780,224

Filing Date: February 9, 2001

Group Art Unit: 1635


Examiner: GUZO, David

For: ADENOVIRAL CAPSID CONTAINING
CHIMERIC PROTEIN IX

**AMENDMENTS TO SPECIFICATION MADE IN RESPONSE TO NOTICE TO
COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE
AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Page 11, Paragraph 0029 is amended as follows:

[0029] The base adenovirus vector, the so-called doubly ablated vector, has a fiber gene with the mutations S to E at position 408 and RLNAEK (SEQ ID NO: 14) to SLNGGG (SEQ ID NO: 15) between the positions 412-417, of the AB loop of the fiber gene, which reduces the affinity of the vector for native cell-surface binding sites (see Roelvink et al., *Science*, 286, 1568-71 (1999)). The penton lacks the sequence RGD present in the RGD loop of wild-type penton proteins, which serves as an internalization sequence for the adenoviral vector. Furthermore, the E1 region in this vector has been replaced with a construct, which consists of a bleomycin resistance gene, and an insect N-defensin gene under control of the *E. coli* lac promoter. The nucleic acids encoding the chimeric protein IX mutants, present on a small and easily manipulated cloning vector, are recombined into the E1 region of the doubly ablated adenoviral vector using methods known to those skilled in the art. This also introduces a CMV promoter-driven marker enzyme gene such as luciferase into the E1 region.



PATENT
Attorney Docket No. 208859

RECEIVED
JUL 11 2002
TECH CENTER 600 2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

ROELVINK et al.

Application No. 09/780,224

Filing Date: February 9, 2001

Group Art Unit: 1635

Examiner: GUZO, David

For: ADENOVIRAL CAPSID CONTAINING
CHIMERIC PROTEIN IX

**AMENDMENT AND
RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE
AND/OR AMINO ACID SEQUENCE DISCLOSURES**

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

In response to the Examiner's Communication and Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated June 21, 2002, please enter the following amendments and consider the following remarks:

AMENDMENTS

IN THE SPECIFICATION:

Page 11, please amend Paragraph 0029 to read as follows:

[0029] The base adenovirus vector, the so-called doubly ablated vector, has a fiber gene with the mutations S to E at position 408 and RLNAEK (SEQ ID NO: 14) to SLNGGG (SEQ ID NO: 15) between the positions 412-417, of the AB loop of the fiber gene, which reduces the affinity of the vector for native cell-surface binding sites (see Roelvink et al., *Science*, 286, 1568-71 (1999)). The penton lacks the sequence RGD present in the RGD loop of wild-type penton proteins, which serves as an internalization